Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTC4S | Q16873 | 5/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743184 | 0.91 | SRD5A2 (0.47) | LTC4SSRD5A2AKR1C3AKR1C2NPC1 | |
| SCHEMBL2743180 | 0.88 | LTC4S (0.47) | LTC4SEPHX2SRD5A2AKR1C3AKR1C2 | |
| SCHEMBL2743179 | 0.87 | LTC4S (0.47) | LTC4SEPHX2SRD5A2AKR1C3AKR1C2 | |
| SCHEMBL2743185 | 0.87 | MAPK13 (0.47) | LTC4SSRD5A2NPC1RAB9A | |
| SCHEMBL231402 | 0.81 | SRD5A2 (0.59) | SRD5A2AKR1C3AKR1C2 | |
| SCHEMBL2743191 | 0.80 | MEN1 (0.44) | LTC4SRAB9A | |
| SCHEMBL232721 | 0.79 | P2RX3 (0.42) | LTC4SSRD5A2 | |
| SCHEMBL2743190 | 0.79 | LTC4S (0.46) | LTC4SSRD5A2AKR1C3AKR1C2 | |
| SCHEMBL2743182 | 0.79 | MAPT (0.43) | LTC4SSRD5A2AKR1C3AKR1C2NPC1 | |
| SCHEMBL232237 | 0.79 | SRD5A2 (0.56) | LTC4SSRD5A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | LTC4S 1/4885EPHX2 296/4885SRD5A2 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.